Tıp Fakültesi / Faculty of Medicine

Permanent URI for this collectionhttps://hdl.handle.net/11727/1403

Browse

Filters

2014 - 20193

Settings

Has files: NoSubject: search.filters.subject.immunosuppression

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Management of Chronic Hepatitis in Special Hosts and Special Situations: A Consensus Report of the Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases
    (2014) Mistik, Resit; Aydin, Mehtap; Aksoy, Suleyman; Altin, Nilgun; Altunal, Nilsun; Avsar, Kemal; Bezirgan, Selma; Buke, Cagri; Celik, Ali Kutta; Celik, Ekrem; Dikici, Nebahat; Hizel, Kenan; Iskender, Serap; Kaya, Ali; Korkmaz, Fatime; Kose, Sukran; Sacligil, Cahide; Sirmatel, Fatma; Tarakci, Huseyin; Turgut, Huseyin; Tutuncu, Ediz; Yulugkural, Zerrin; https://orcid.org/0000-0003-4044-9366; HLX-0937-2023
    Study Group for Viral Hepatitis of the Turkish Society of Clinical Microbiology and Infectious Diseases convened a meeting to develop a consensus report on management of chronic hepatitis in special hosts and special situations. Relevant literature and international guidelines were reviewed, and recommendations agreed are presented at the end of each section such as therapy of chronic hepatitis B (CHB) in patients with compensated and decompensated cirrhosis, prevention and therapy of recurrent hepatitis B after liver transplantation, management of fulminant hepatitis B, therapy of CHB in hemodialysis patients, management of CHB in nonliver solid organ transplant recipients, management of CHB in immunosuppressed nontransplant patients, therapy of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) coinfection, management of HBV and hepatitis C virus (HCV) coinfection, management of CHB in alcoholic patients and injecting drug users, therapy of CHB in pregnancy and lactation period, extrahepatic manifestations in HBV infection, HBV, HCV and hepatitis D virus coinfection, therapy of chronic hepatitis C (CHC) in patients with compensated and decompensated cirrhosis, treatment of patients with recurrent HCV infection following liver transplantation, therapy of CHC in hemodialysis patients, management of CHC in nonliver solid organ transplant recipients, therapy of HCV, HBV and HIV coinfection, management of CHC in immunosuppressed nontransplant patients, HCV infection and biological agents, HCV infection and chemotherapy, management of CHC in alcoholic patients and injecting drug users, fatty liver and CHC, hemoglobinopathy and CHC, CHC in pregnancy and lactation period, extrahepatic manifestations in HCV infection.
  • No Thumbnail Available
    Item
    Reactivation of Resolved Hepatitis B Virus Infection Before The Relapse of Lymphoma : Immunosuppressive Effect of the Lymphoproliferative Disorders ?
    (2016) Gokturk, Huseyin Savas; Unler, Gulhan Kanat; Gokturk, Bahar; https://orcid.org/0000-0003-0182-002X; 26852769
    Hepatitis B virus (HBV) infection is a heterogeneous disease with distinct phases determined mainly by the interaction between virus replication and host immune response. HBV reactivation can occur spontaneously, developing resistance to antiviral treatment while the patient is undergoing treatment, after cessation of antiviral drugs, or be triggered by immunosuppressive drugs and chemotherapy. HBV reactivation can be severe and sometimes fatal because of liver failure. Here we report a patient with resolved HBV infection who presented with reactivation before being diagnosed with a relapse of non-Hodgkin lymphoma.
  • No Thumbnail Available
    Item
    Management of Kaposi sarcoma after solid organ transplantation: A European retrospective study
    (2019) Delyon, Julie; Rabate, Clementine; Euvrard, Sylvie; Harwood, Catherine A.; Proby, Charlotte; Gulec, Tulin; Seckin, Deniz; Del Marmol, Veronique; Bouwes-Bavinck, Jan Nico; Ferrandiz-Pulido, Carla; Ocampo, Maria Andrea; Barete, Stephane; Legendre, Christophe; Frances, Camille; Porcher, Raphael; Lebbe, Celeste; 30902727
    Background: Systemic therapeutic management of post-transplant Kaposi sarcoma (KS) is mainly based on 3 axes: reduction of immunosuppression, conversion to mammalian target of rapamycin (mTOR) inhibitors, chemotherapy, or a combination of these. Objective: To obtain an overview of clinical strategies about the current treatment of KS. Methods: We conducted a multicenter retrospective cohort study including 145 solid organ transplant recipients diagnosed with KS between 1985 and 2011 to collect data regarding first-line treatment and response at 6 months. Results: Overall, 95%, 28%, and 16% of patients had reduction of immunosuppression, conversion to mTOR inhibitor, and chemotherapy, respectively. Patients treated with chemotherapy or mTOR inhibitor conversion were more likely to have visceral KS. At 6 months, 83% of patients had response, including 40% complete responses. Limitations: The retrospective design of the study. Conclusion: Currently available therapeutic options seem to be effective to control KS in most patients. Tapering down the immunosuppressive regimen remains the cornerstone of KS management.